Loading...

We've got a brand new version of Simply Wall St! Try it out

Luminex

Nasdaq:LMNX
Snowflake Description

Flawless balance sheet with reasonable growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LMNX
Nasdaq
$900M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. The last earnings update was 13 days ago. More info.


Add to Portfolio Compare Print
LMNX Share Price and Events
7 Day Returns
3.5%
NasdaqGS:LMNX
4.8%
US Life Sciences
0.7%
US Market
1 Year Returns
-24.8%
NasdaqGS:LMNX
18.7%
US Life Sciences
13.7%
US Market
LMNX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Luminex (LMNX) 3.5% -0.3% -1.8% -24.8% -5.1% 7%
US Life Sciences 4.8% 6.7% 5.4% 18.7% 93.2% 117.8%
US Market 0.7% 4.7% 6.1% 13.7% 39.2% 44.5%
1 Year Return vs Industry and Market
  • LMNX underperformed the Life Sciences industry which returned 18.7% over the past year.
  • LMNX underperformed the Market in United States of America which returned 13.7% over the past year.
Price Volatility
LMNX
Industry
5yr Volatility vs Market

LMNX Value

 Is Luminex undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Luminex to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Luminex.

NasdaqGS:LMNX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-09-30) in USD $ .360000
Payout Ratio Company Filings (2019-09-30) 2918.6%
Discount Rate (Cost of Equity) See below 9.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:LMNX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.024 (1 + (1- 21%) (2.6%))
1.138
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.14
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.138 * 5.96%)
9.51%

Discounted Cash Flow Calculation for NasdaqGS:LMNX using Dividend Discount Model Model

The calculations below outline how an intrinsic value for Luminex is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

NasdaqGS:LMNX Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= $0.36 / (9.51% - 2.73%)
$5.31
NasdaqGS:LMNX Discount to Share Price
Calculation Result
Value per share (USD) From above. $5.31
Current discount Discount to share price of $19.97
= -1 x ($19.97 - $5.31) / $5.31
-276.1%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Luminex is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Luminex's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Luminex's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:LMNX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.21
NasdaqGS:LMNX Share Price ** NasdaqGS (2019-11-18) in USD $19.97
United States of America Life Sciences Industry PE Ratio Median Figure of 18 Publicly-Listed Life Sciences Companies 33.43x
United States of America Market PE Ratio Median Figure of 2,924 Publicly-Listed Companies 18.25x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Luminex.

NasdaqGS:LMNX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:LMNX Share Price ÷ EPS (both in USD)

= 19.97 ÷ -0.21

-93.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Luminex is loss making, we can't compare its value to the US Life Sciences industry average.
  • Luminex is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Luminex's expected growth come at a high price?
Raw Data
NasdaqGS:LMNX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -93.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
96.3%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 15 Publicly-Listed Life Sciences Companies 2.74x
United States of America Market PEG Ratio Median Figure of 2,038 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Luminex, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Luminex's assets?
Raw Data
NasdaqGS:LMNX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $10.40
NasdaqGS:LMNX Share Price * NasdaqGS (2019-11-18) in USD $19.97
United States of America Life Sciences Industry PB Ratio Median Figure of 36 Publicly-Listed Life Sciences Companies 5.07x
United States of America Market PB Ratio Median Figure of 5,086 Publicly-Listed Companies 1.76x
NasdaqGS:LMNX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:LMNX Share Price ÷ Book Value per Share (both in USD)

= 19.97 ÷ 10.40

1.92x

* Primary Listing of Luminex.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Luminex is good value based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess Luminex's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. Luminex has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LMNX Future Performance

 How is Luminex expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
96.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Luminex expected to grow at an attractive rate?
  • Luminex's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Luminex's earnings growth is expected to exceed the United States of America market average.
  • Luminex's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:LMNX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:LMNX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 96.3%
NasdaqGS:LMNX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 7.8%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 17.3%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:LMNX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:LMNX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 389 6 1
2020-12-31 363 7 -3 5
2019-12-31 335 7 -9 4
2019-11-18
NasdaqGS:LMNX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 325 13 -9
2019-06-30 319 18 -3
2019-03-31 316 30 8
2018-12-31 316 51 18
2018-09-30 313 70 18
2018-06-30 315 68 33
2018-03-31 311 73 33
2017-12-31 307 57 29
2017-09-30 301 48 28
2017-06-30 298 39 14
2017-03-31 285 40 14
2016-12-31 271 50 14

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Luminex's earnings are expected to grow significantly at over 20% yearly.
  • Luminex's revenue is expected to grow by 7.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:LMNX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Luminex Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:LMNX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.14 0.14 0.14 1.00
2020-12-31 0.02 0.10 -0.07 2.00
2019-12-31 -0.18 -0.17 -0.19 2.00
2019-11-18
NasdaqGS:LMNX Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.21
2019-06-30 -0.06
2019-03-31 0.18
2018-12-31 0.42
2018-09-30 0.40
2018-06-30 0.76
2018-03-31 0.76
2017-12-31 0.67
2017-09-30 0.66
2017-06-30 0.32
2017-03-31 0.33
2016-12-31 0.32

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Luminex will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Luminex's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Luminex has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LMNX Past Performance

  How has Luminex performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Luminex's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Luminex does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Luminex's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Luminex's 1-year growth to the US Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
Luminex's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Luminex Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:LMNX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 325.27 -9.44 125.42 56.47
2019-06-30 319.04 -2.52 120.31 55.20
2019-03-31 315.56 7.91 114.78 51.89
2018-12-31 315.82 18.20 109.12 47.16
2018-09-30 312.88 17.55 108.50 44.36
2018-06-30 314.58 33.14 109.21 43.04
2018-03-31 311.45 33.03 109.15 43.62
2017-12-31 306.57 28.89 107.32 45.72
2017-09-30 300.64 28.43 105.97 48.69
2017-06-30 297.73 13.89 105.31 50.78
2017-03-31 285.44 14.10 99.95 50.06
2016-12-31 270.64 13.81 96.31 48.66
2016-09-30 258.82 37.55 91.96 46.27
2016-06-30 248.20 41.20 86.81 43.60
2016-03-31 242.95 38.18 85.64 43.56
2015-12-31 237.71 36.86 84.76 42.69
2015-09-30 235.37 39.29 82.69 42.16
2015-06-30 231.45 38.43 82.87 42.40
2015-03-31 228.16 40.53 82.82 42.20
2014-12-31 226.98 39.04 82.79 43.14
2014-09-30 224.03 21.36 81.71 42.91
2014-06-30 218.13 16.60 81.75 42.93
2014-03-31 216.78 15.57 80.98 43.41
2013-12-31 213.42 7.10 87.30 45.04
2013-09-30 213.80 6.23 82.68 45.47
2013-06-30 213.07 7.11 80.68 46.31
2013-03-31 207.06 6.37 77.18 44.67
2012-12-31 202.58 12.41 68.33 42.99

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Luminex has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Luminex has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Luminex improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Luminex's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Luminex has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LMNX Health

 How is Luminex's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Luminex's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Luminex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Luminex's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Luminex's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Luminex has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Luminex Company Filings, last reported 1 month ago.

NasdaqGS:LMNX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 459.91 0.00 66.05
2019-06-30 465.99 0.00 63.33
2019-03-31 468.46 0.00 61.69
2018-12-31 467.66 0.00 76.44
2018-09-30 468.21 0.00 146.89
2018-06-30 465.53 0.00 139.00
2018-03-31 457.01 0.00 128.66
2017-12-31 437.91 0.00 127.11
2017-09-30 438.18 0.00 110.91
2017-06-30 418.59 0.00 103.71
2017-03-31 409.87 0.00 86.47
2016-12-31 403.68 0.00 93.45
2016-09-30 402.77 0.00 84.15
2016-06-30 394.96 0.00 81.72
2016-03-31 377.23 0.00 148.31
2015-12-31 368.54 0.00 140.53
2015-09-30 342.51 0.00 131.56
2015-06-30 332.39 0.00 121.07
2015-03-31 327.07 0.00 94.91
2014-12-31 319.99 0.00 91.69
2014-09-30 294.87 0.00 89.12
2014-06-30 285.85 0.00 89.71
2014-03-31 276.14 1.61 81.90
2013-12-31 269.62 1.66 72.44
2013-09-30 258.90 1.71 62.67
2013-06-30 250.55 1.67 42.97
2013-03-31 253.32 2.81 60.89
2012-12-31 259.67 2.84 56.40
  • Luminex has no debt.
  • Luminex currently has no debt however we can't compare to 5 years ago as we have no data for that period.
  • Luminex has no debt, it does not need to be covered by operating cash flow.
  • Luminex has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Luminex's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Luminex has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LMNX Dividends

 What is Luminex's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.8%
Current annual income from Luminex dividends.
If you bought $2,000 of Luminex shares you are expected to receive $36 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Luminex's pays a higher dividend yield than the bottom 25% of dividend payers in United States of America (1.42%).
  • Luminex's dividend is below the markets top 25% of dividend payers in United States of America (3.65%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:LMNX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1956 Stocks 2.3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:LMNX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2019-12-31
2019-11-18
NasdaqGS:LMNX Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-11-05 0.360 1.886
2019-11-04 0.360 1.915
2019-08-01 0.360 1.741
2019-07-31 0.360 1.662
2019-05-21 0.240 1.156
2019-02-08 0.240 1.018
2018-12-11 0.240 0.964
2018-09-11 0.240 0.853
2018-05-18 0.240 0.813
2018-01-24 0.240 1.129
2017-12-13 0.240 1.177
2017-09-12 0.240 1.160
2017-05-24 0.240 1.190
2017-02-21 0.240 1.270

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, Luminex has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but Luminex only paid a dividend in the past 3 years.
Current Payout to shareholders
What portion of Luminex's earnings are paid to the shareholders as a dividend.
  • The company is paying a dividend however it is incurring a loss.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Luminex's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Luminex afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Luminex has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LMNX Management

 What is the CEO of Luminex's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Homi Shamir
COMPENSATION $3,689,541
AGE 65
TENURE AS CEO 5.1 years
CEO Bio

Mr. Nachum Shamir, also known as Homi, has been Chief Executive Officer and President of Luminex Corporation since October 15, 2014. Mr. Shamir served as Chief Executive Officer and President of Given at IDB Holding Corporation Ltd from 2006 to 2014. He served as the Chief Executive Officer and President of Given Imaging Ltd. at Sierra Scientific Instruments, LLC and Elron Electronic Industries Ltd. from April 9, 2006 to June 2014. Mr. Shamir served as the President of Kodak Versamark, Inc. since January 2004 and also served as its Chief Executive Officer. He served as the President of Transaction & Industrial Solutions of Eastman Kodak Graphic Communications Group from April 2005 to December 2005 and Corporate Vice President of Eastman Kodak Co. from January 20, 2004 to December 2005. Mr. Shamir joined Scitex in 1993 as Managing Director of the Asia-Pacific and Japan regions for Scitex Digital Printing Inc., a subsidiary of Scailex Corp., Ltd., where he was responsible for positioning Scitex as a regional leader in high-speed, variable information technology. From January 2001 to January 2004, he served as the Chief Executive Officer and President of Scitex Digital Printing and also served as its Chief Operating Officer since July 2000. Mr. Shamir served as the Managing Director and General Manager of Scitex Digital Printing (Asia Pacific) Pte Ltd., from the incorporation of this Singapore-based company in 1994. From 1993 to 1994 he worked with the Hong Kong based Scitex Asia Pacific (H.K.) Ltd. From June 2003 to January 2004, Mr. Shamir served as the President and Chief Executive Officer of Scitex Corporation. He spent 16 years in the Asia-Pacific region holding executive-level positions for a number of companies in Hong Kong, Australia, Fiji and the Philippines. He was a Director of Cogentix Medical, Inc. since November 3, 2016 until April 23, 2018. He has been a Member of Supervisory Board at invendo medical GmbH from June 2014 to October 2017. He has been a Director of Luminex Corporation October 15, 2014. He serves on the board of the Victoria Theatre in Dayton, as an Executive Director of the printing industry's EDSF association and on the external advisory board of the College of Engineering and Computer Science at Wright State University. Mr. Shamir served as a Director of Given Imaging Inc. since April 9, 2006. He has been a Director of Strata Skin Sciences, Inc. since May 29, 2018. He served as a Director of Scailex Corp., Ltd. since April 25, 2004, Given Imaging Ltd. from April 9, 2006 to June 2014. He is a frequently featured speaker and award recipient, the most recent being the On Demand Pioneer Award in April 2003. He earned a Masters Degree in Public Administration from Harvard University in 1990 and a Bachelor of Science Degree from Hebrew University in Jerusalem in 1980.

CEO Compensation
  • Homi's compensation has increased whilst company is loss making.
  • Homi's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Luminex management team in years:

4.7
Average Tenure
56
Average Age
  • The tenure for the Luminex management team is about average.
Management Team

Homi Shamir

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
65
TENURE
5.1 yrs

Harriss Currie

TITLE
CFO, Senior VP of Finance & Treasurer
COMPENSATION
$1M
AGE
57
TENURE
17.1 yrs

Richard Rew

TITLE
Senior VP
COMPENSATION
$976K
AGE
51
TENURE
4.7 yrs

Todd Bennett

TITLE
Senior Vice President of Global Sales & Customer Operations
COMPENSATION
$925K
AGE
49
TENURE
3 yrs

Randy Myers

TITLE
Senior Vice President of Global Manufacturing & Quality
COMPENSATION
$911K
AGE
57
TENURE
4.7 yrs

Kendel Martin

TITLE
Vice President of Accounting
TENURE
11.9 yrs

Jeff Christensen

TITLE
Senior Director of Investor Relations

Eric Shapiro

TITLE
Senior Vice President of Global Marketing
AGE
55
TENURE
4.1 yrs

Nancy Fairchild

TITLE
Senior Vice President of Human Resources
COMPENSATION
$749K
AGE
65
TENURE
4.8 yrs

Chuck Collins

TITLE
Senior Vice President of Research & Development
AGE
42
TENURE
1.8 yrs
Board of Directors Tenure

Average tenure and age of the Luminex board of directors in years:

10.5
Average Tenure
65
Average Age
  • The average tenure for the Luminex board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Wally Loewenbaum

TITLE
Independent Chairman
COMPENSATION
$363K
AGE
74
TENURE
17.2 yrs

Homi Shamir

TITLE
CEO, President & Director
COMPENSATION
$4M
AGE
65
TENURE
5.1 yrs

Jim Kever

TITLE
Independent Director
COMPENSATION
$177K
AGE
66
TENURE
22.9 yrs

Kevin McNamara

TITLE
Independent Director
COMPENSATION
$214K
AGE
62
TENURE
16.5 yrs

Tom Erickson

TITLE
Independent Director
COMPENSATION
$177K
AGE
68
TENURE
15.5 yrs

Ed Ogunro

TITLE
Independent Director
COMPENSATION
$177K
AGE
66
TENURE
10.5 yrs

Ken Samet

TITLE
Independent Director
AGE
61
TENURE
0.9 yrs

Stephen Eck

TITLE
Independent Director
COMPENSATION
$147K
AGE
64
TENURE
3.7 yrs

Dijuana Lewis

TITLE
Independent Director
AGE
60
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Luminex individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Nov 19 Buy Nachum Shamir Individual 11. Nov 19 11. Nov 19 5,000 $19.30 $96,482
08. Nov 19 Buy George Loewenbaum Individual 07. Nov 19 08. Nov 19 81,657 $18.14 $1,469,432
27. Aug 19 Buy Nachum Shamir Individual 26. Aug 19 26. Aug 19 5,000 $19.71 $98,528
X
Management checks
We assess Luminex's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Luminex has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LMNX News

Simply Wall St News

CEO, President & Director Nachum Shamir Just Bought Shares In Luminex Corporation (NASDAQ:LMNX)

See our latest analysis for Luminex Luminex Insider Transactions Over The Last Year In fact, the recent purchase by Nachum Shamir was the biggest purchase of Luminex shares made by an insider individual in the last twelve months, according to our records. … NasdaqGS:LMNX Recent Insider Trading, August 30th 2019 Does Luminex Boast High Insider Ownership? … When combined with notable insider ownership, these factors suggest Luminex insiders are well aligned, and that they may think the share price is too low.

Simply Wall St -

What Kind Of Shareholder Owns Most Luminex Corporation (NASDAQ:LMNX) Stock?

Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. … Check out our latest analysis for Luminex NasdaqGS:LMNX Ownership Summary, August 21st 2019 What Does The Institutional Ownership Tell Us About Luminex? … Insider Ownership Of Luminex The definition of company insiders can be subjective, and does vary between jurisdictions.

Simply Wall St -

The Luminex (NASDAQ:LMNX) Share Price Is Down 41% So Some Shareholders Are Getting Worried

Investors in Luminex Corporation (NASDAQ:LMNX) have tasted that bitter downside in the last year, as the share price dropped 41%. … There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … Investors should note that there's a difference between Luminex's total shareholder return (TSR) and its share price change, which we've covered above.

Simply Wall St -

Does Luminex Corporation's (NASDAQ:LMNX) CEO Salary Compare Well With Others?

According to our data, Luminex Corporation has a market capitalization of US$907m, and pays its CEO total annual compensation worth US$3.7m. … Thus we can conclude that Homi Shamir receives more in total compensation than the median of a group of companies in the same market, and of similar size to Luminex Corporation. … We compared total CEO remuneration at Luminex Corporation with the amount paid at companies with a similar market capitalization.

Simply Wall St -

Does Luminex Corporation (NASDAQ:LMNX) Have A Particularly Volatile Share Price?

Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

What Kind Of Share Price Volatility Should You Expect For Luminex Corporation (NASDAQ:LMNX)?

Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market. … What this means for you: One potential advantage of owning low beta stocks like Luminex is that your overall portfolio won't be too sensitive to overall market movements.

Simply Wall St -

Is Luminex Corporation's (NASDAQ:LMNX) ROE Of 1.7% Concerning?

The formula for return on equity is: Return on Equity = Net Profit ÷ Shareholders' Equity Or for Luminex: 1.7% = US$7.9m ÷ US$468m (Based on the trailing twelve months to March 2019.) It's easy to understand the 'net profit' part of that equation, but 'shareholders' equity' requires further explanation. … Combining Luminex's Debt And Its 1.7% Return On Equity While Luminex does have a tiny amount of debt, with debt to equity of just 0.055, we think the use of debt is very modest. … Careful use of debt to boost returns is often very good for shareholders.

Simply Wall St -

Have Insiders Been Selling Luminex Corporation (NASDAQ:LMNX) Shares?

So we'll take a look at whether insiders have been buying or selling shares in Luminex Corporation (NASDAQ:LMNX). … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … While insider selling is a negative, to us, it is more negative if the shares are sold at a lower price

Simply Wall St -

Should Luminex Corporation (NASDAQ:LMNX) Be Part Of Your Portfolio?

Dividend paying stocks like Luminex Corporation (NASDAQ:LMNX) tend to be popular with investors, and for good reason - some research shows that a significant amount of all stock market returns come from reinvested dividends. … Yet sometimes, investors buy a popular dividend stock because of its yield, and then lose money if the company's dividend doesn't live up to expectations. … With only a two-year payment history, and a 1.0% yield, investors probably think Luminex is not much of a dividend stock.

Simply Wall St -

Luminex Corporation (NASDAQ:LMNX): Is Growth Priced In?

Luminex Corporation (NASDAQ:LMNX) is considered a high-growth stock, but its last closing price of $23.51 left some investors wondering if this high future earnings potential can be rationalized by its current price tag. … View our latest analysis for Luminex? … According to the analysts covering the company, the following few years should bring about good growth prospects for Luminex

Simply Wall St -

LMNX Company Info

Description

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; TDAS, an analysis program designed for development and optimization of nucleic acid assays; IDEAS, an image analysis software; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group A strep assays, ARIES bordetella assays, ARIES GBS assay, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Details
Name: Luminex Corporation
LMNX
Exchange: NasdaqGS
Founded: 1995
$899,686,582
45,051,907
Website: http://www.luminexcorp.com
Address: Luminex Corporation
12212 Technology Boulevard,
Austin,
Texas, 78727,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS LMNX Common Stock Nasdaq Global Select US USD 30. Mar 2000
DB LMX Common Stock Deutsche Boerse AG DE EUR 30. Mar 2000
Number of employees
Current staff
Staff numbers
988
Luminex employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 23:40
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/11/11
Last earnings filing: 2019/11/05
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.